CARTITUDE-4 Data to Redefine Treatment of Multiple Myeloma: Legend Biotech's Key Reveal on Minimal Residual Disease

Legend Biotech Corporation, a global leader in cell therapy, is set to present exciting new findings from the Phase 3 CARTITUDE-4 trial at the 66th Annual American Society of Hematology (ASH) Annual Meeting in San Diego. The data will focus on minimal residual disease (MRD) negativity rates in multiple myeloma patients treated with CARVYKTI® (cilta cartagene autoleucel; cilta-cel) compared to standard of care. The trial investigated lenalidomide-refractory patients who had received one to three prior lines of therapy. The oral presentation is scheduled for Monday, December 9, 2024, at 5:45 p.m. PT.

The data from the CARTITUDE-4 trial played a pivotal role in securing the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals for CARVYKTI® earlier this year. The treatment is now authorised for adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy (LOT), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and are refractory to lenalidomide. As the first and only BCMA-targeted CAR-T cell therapy approved for this patient group, CARVYKTI® is now available in five countries and has been administered to over 4,000 patients worldwide.

Ying Huang, Ph. D., Chief Executive Officer of Legend Biotech, said in a statement, “This year’s ASH data continues to highlight our advances across key clinical areas aimed at helping healthcare professionals decide the optimal treatment regimens for their patients with multiple myeloma. MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. The significantly increased overall and sustained MRD negativity rates reinforce CARVYKTI as a transformative therapeutic option versus the standard of care for multiple myeloma patients as early as the second line.”